Background: Prostate cancer is a common disease in men over 50 years. Only early detection by screening can guarantee a favourable outcome. Objective: The objective of the study is to report on the practice of prostate cancer screening by general practitioners in Lomé. Material and Method: This was a practice survey. A questionnaire administered to general practitioners allowed to examine the following parameters: the practitioner’s years of practice, the screening criteria, the screening tools and the factors motivating the request for urological advice. The data were analysed using the software Epi info 7.1.5. The P value was considered significant below 0.05. Results: One hundred and eighty (180) physicians average-aged 29 were administered among whom one hundred and fifty-seven (157) males and twenty-three (23) females. The average duration of the medical practice was 35.2 months (6 months - 204 months). The screening criteria were age (47.2%), family history of cancer (17.8%), and age over 50 years associated with symptoms of the low urinary tract (35%). The practitioner’s experience did not affect these criteria (p = 0.12). The screening tools were the digital rectal examination (DRE) associated with prostate specific antigen (PSA) assay (20.5%), PSA alone (29.5%), DRE alone (6.6%), suprapubic ultrasound (32.3%) and endorectal ultrasound (11.1%). The choice of the screening tool was related to the practitioner’s experience (p = 0.03). The determining factor for a urological consultation was a high PSA (>4 ng/ml) independent of the DRE. Conclusion: Prostate cancer screening is largely done by general practitioners in Lomé. However, the use of some criteria and tools for the screening is not optimal.
References
[1]
Siegel, R.L., Miller, K.D. and Jemal, A. (2017) Cancer Statistics, 2017. CA: A Cancer Journal for Clinicians, 67, 7-30. https://doi.org/10.3322/caac.21387
[2]
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., et al. (2015) Cancer Incidence and Mortality Worldwide: Sources, Methods and Major Patterns in GLOBOCAN 2012. International Journal of Cancer, 136, E359-E38. https://doi.org/10.1002/ijc.29210 6.
[3]
Schroder, F.H., Hugosson, J., Roobol, M.J., Tammela, T.L.J., Ciatto, S., Nelen, V., et al. (2009) Screening and Prostate-Cancer Mortality in a Randomized European Study. The New England Journal of Medicine, 360, 1320-1328. https://doi.org/10.1056/NEJMoa0810084
[4]
Mongiat-Artus, P. and Teillac, P. (2006) Dépistage du cancer de la prostate: Synthèse. Annales d’Urologie, 40, 106-110. https://doi.org/10.1016/j.anuro.2006.01.009
[5]
Perrin, P. (2008) Dépistage du cancer de la prostate: Les arguments 《contre》. Médecine Nucléaire, 32, 41-45. https://doi.org/10.1016/j.mednuc.2007.11.005
[6]
Cassell, A., Yunusa, B., Jalloh, M., Mbodji, M.M., Diallo, A., Ndoye, M., et al. (2019) A Review of Localized Prostate Cancer: An African Perspective. World Journal of Oncology, 10, 162-168. https://doi.org/10.14740/wjon1221
[7]
Ferlay, J.E.M., Lam, F., Colombet, M., Mery, L., Pineros, M., Znaor, A., Soerjomataram, I., et al. (2019) Global Cancer Observatory: Cancer Tomorrow. International Agency for Research on Cancer, Lyon. https://gco.iarc.fr/tomorrow
[8]
Tengué, K., Kpatcha, T.M., Botcho, G., Leloua, E., Amavi, A.K., Sikpa, K., Sewa, E., Anoukoum, T., Amegbor, K. and Dosseh, E. (2016) Profilépidémiologique, diagnostique, thérapeutiqueetévolutif du cancer de la prostate au Togo. African Journal of Urology, 22, 76-82. https://doi.org/10.1016/j.afju.2015.06.006
[9]
Labbé, D.P., Zadra, G., Yang, M., Reyes, J.M., Lin, C.Y., Cacciatore, S., et al. (2019) High-Fat Diet Fuels Prostate Cancer Progression by Rewiring the Metabolome and Amplifying the MYC Program. Nature Communications, 10, Article No. 4358. https://doi.org/10.1038/s41467-019-12298-z
[10]
Mottet, N., Comford, P., Van der Bergh, R.C.N., Briers, E., De Santis, M., Gillesen, S., Grummet, J., Henry, A.M., Van der Kwast, T.H., Lam, T.B., Masson, M.D., O’Hanlon, S., Oprea-Lager, D.E., Ploussard, G., Van der Poel, H.G., Rouvière, O., Schoots, I.G., Tilki, D., Wiegel, T., Van den Broeck, T., Cumberbatch, M., Farolfi, A., Fossati, N., Gandaglia, G., Grivas, N., Lardas, M., Liew, M., Moris, L. and Willemse, P.-P.M. (2021) EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer in European Association of Urology Pocket Guideline. 2021 Edition, European Association of Urology (EAU), Arnhem, 74-75.
[11]
Kupelian, P., Klein, E., Witte, J., Kuppelian, V. and Suh, J. (1997) Familial Prostate Cancer: A Different Disease? Journal of Urology, 158, 2197-2201. https://doi.org/10.1016/S0022-5347(01)68194-1
[12]
Westerman, M.E., Gershman, B., Karnes, R.J., Thompson, R.H., Rangel, L. and Boorjian, S.A. (2015) Impact of a Family History of Prostate Cancer on Clinicopathologic Outcomes and Survival Following Radical Prostatectomy. World Journal of Urology, 8, 1115-1122. https://doi.org/10.1007/s00345-015-1738-6
[13]
Jansson, K.F., Akre, O., Garmo, H., Bill-Axelson, A., Adolfsson, J., Stattin, P., et al. (2012) Concordance of Tumor Differentiation among Brothers with Prostate Cancer. European Urology, 62, 656-661. https://doi.org/10.1016/j.eururo.2012.02.032
[14]
Brandt, A., Bermejo, J.L., Sundquist, J. and Hemminki, K. (2010) Age-specific Risk of Incident Prostate Cancer and Risk of Death from Prostate Cancer Defined by the Number of Affected Family Members. European Urology, 58, 275-280. https://doi.org/10.1016/j.eururo.2010.02.002
[15]
Kamangar, F., Dores, G.M. and Anderson, W.F. (2006) Patterns of Cancer Incidence, Mortality, and Prevalence across Five Continents: Defining Priorities to Reduce Cancer Disparities in Different Geographic Regions of the World. Journal of Clinical Oncology, 24, 2137-2150. https://doi.org/10.1200/JCO.2005.05.2308
[16]
Chornokur, G., Dalton, K., Borysova, M.E. and Kumar, N.B. (2011) Disparities at Presentation, Diagnosis, Treatment, and Survival in African American Men, Affected by Prostate Cancer. Prostate, 71, 985-97. https://doi.org/10.1002/pros.21314
[17]
Karami, S., Young, H.A. and Henson, D.E. (2007) Earlier Age at Diagnosis: Another Dimension in Cancer Disparity? Cancer Detection and Prevention, 31, 29-34. https://doi.org/10.1016/j.cdp.2006.11.004
[18]
Naji, L., Randhawa, H., Sohani, Z., Dennis, B., Lautenbach, D., Kavanagh, O., et al. (2018) Digital Rectal Examination for Prostate Cancer Screening in Primary Care: A Systematic Review and Meta-Analysis. The Annals of Family Medicine, 16, 149-154. https://doi.org/10.1370/afm.2205
[19]
Richie, J.P., Catalona, W.J., Ahmann, F.R., Hudson, M.A., Scardino, P.T., Flanigan, R.C., et al. (1993) Effect of Patient Age on Early Detection of Prostate Cancer with Serum Prostate Specific Antigen and Digital Rectal Examination. Urology, 42, 365-374. https://doi.org/10.1016/0090-4295(93)90359-I
[20]
Stormont, T.J., Farrow, G.M., Myers, R.P., Blute, M.L., Zincke, H., Wilson, T.M. and Oesterling, J.E. (1993) Clinical Stage BO or T1c Prostate Cancer: Nonpalpable Disease Identified by Elevated Serum Prostate-Specific Antigen Concentration. Urology, 41, 3-8. https://doi.org/10.1016/0090-4295(93)90233-Z
[21]
Schroder, F.H., Hugosson, J., Roobol, M.J., Tammela, T.L.J., Zappa, M., Nelen, V., et al. (2014) Screening and Prostate Cancer Mortality: Results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 Years of Follow-up. Lancet, 384, 2027-2035. https://doi.org/10.1016/S0140-6736(14)60525-0
[22]
Schroder, F.H., Hugosson, J., Roobol, M.J., Tammela, T.L.J., Ciatto, S., Nelen, V., et al. (2012) Prostate-Cancer Mortality at 11 Years of Follow-up. The New England Journal of Medicine, 366, 981-990. https://doi.org/10.1056/NEJMoa1113135
[23]
Carvalhal, G.F., Smith, D.S., Mager, D.E., Ramos, C. and Catalona, W.J. (1999) Digital Rectal Examination for Detecting Prostate Cancer at Prostate Specific Antigen Levels of 4 ng./ml. or Less. Journal of Urology, 161, 835-839. https://doi.org/10.1016/S0022-5347(01)61785-3
[24]
Okotie, O.T., Roehl, K.A., Han, M., Loeb, S., Gashti, S.N. and Catalona, W.J. (2007) Characteristics of Prostate Cancer Detected by Digital Rectal Examination Only. Urology, 70, 1117-1120. https://doi.org/10.1016/j.urology.2007.07.019
[25]
Gosselaar, C., Roobol, M.J., Roemeling, S. and Schröder, S.H. (2008) The Role of the Digital Rectal Examination in Subsequent Screening Visits in the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam. European Urology, 54, 581-588. https://doi.org/10.1016/j.eururo.2008.03.104
[26]
Thompson, I.M., Pauler, D.K., Goodman, P.J., Tangen, C.M., Lucia, M.S., Parnes, H.L., et al. (2004) Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤ 4.0 ng per milliliter. The New England Journal of Medicine, 350, 2239-2246. https://doi.org/10.1056/NEJMoa031918
